Artelo Biosciences Provides Business Update and Reports 2026 Third Quarter Financial Results
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Artelo Biosciences (ARTL) reported a narrower third-quarter 2026 net loss and advanced clinical development across its pain and glaucoma programs. Net loss was $1.8 million, or $3.19 per basic and diluted share, versus $3.1 million a year earlier. Cash totaled $4.4 million at September 30, 2026.
In an obesity animal model, ART27.13 produced approximately 20% weight loss alone and approximately 40% with semaglutide. Enrollment is underway in the Phase 2 DREAM glaucoma study. Artelo anticipates starting ART26.12’s multiple ascending dose study in the fourth quarter of 2026. ART27.13 formulation patent claims received U.S. and Japanese Notices of Allowance; Artelo expects the U.S. patent, once issued, to provide protection through 2041.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointQ3 2026 net loss narrowed to $1.8 million from $3.1 million in Q3 2025.
- Minor pointR&D expenses fell to $0.8 million in Q3 2026 from $1.3 million a year earlier.
- Minor pointGeneral and administrative expenses fell to $1.0 million in Q3 2026 from $1.8 million a year earlier.
- Minor pointART27.13 produced approximately 20% weight loss alone in an obesity animal model, comparable to semaglutide.
- Minor pointART27.13 plus semaglutide produced approximately 40% weight loss in the obesity animal model.
8 minor points
- Minor pointART27.13 plus semaglutide further improved oral glucose tolerance and increased bone mineral density in the animal model.
- Minor pointPhase 2 DREAM enrollment is underway, testing daily oral ART27.13 for glaucoma or ocular hypertension.
- Minor pointART27.13 formulation patent claims received U.S. and Japanese Notices of Allowance.
- Minor pointART27.13 provisional patent application filed covering obesity and combination use with GLP-1 receptor agonists.
- Minor pointPreviously reported Phase 2 CAReS interim findings showed improved weight, lean body mass and activity in cancer-related anorexia and weight loss.
- Minor point. Forward-looking: it has not happened yet and may not happen.ART26.12 multiple ascending dose study is anticipated to begin in the fourth quarter of 2026.
- Minor pointPreviously reported ART26.12 single ascending dose results showed favorable safety and tolerability, predictable drug exposure and development-supporting exposure levels.
- Minor pointNonclinical ART26.12 osteoarthritis findings showed pain relief comparable to naproxen with significantly less gastric tissue damage.
Negative
- Minor pointU.S. ART27.13 formulation patent issuance remains pending; protection through 2041 is expected only once issued.
News Explained
Artelo reports filing a provisional patent application covering ART27.13 for obesity, both alone and in combination with GLP-1 receptor agonists.
Details
Market move: ARTL -4.55% vs previous close. Q3 2026 earnings report
On Nov 12, the day this news came out, the latest delayed price for ARTL is 4.55% below the previous close. Our momentum scanner has recorded 2 alerts for this stock so far that day. The latest delayed price is $2.10.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Weight loss, ART27.13 monotherapy
- approximately 20%
- Nonclinical diet-induced obesity animal model
- Weight loss, ART27.13 plus semaglutide
- approximately 40%
- Nonclinical diet-induced obesity animal model
- Expected U.S. patent protection
- through 2041
- ART27.13 intended commercial formulation; once the patent is issued
- ART26.12 multiple ascending dose study
- fourth quarter of 2026
- Planned Phase 1 study initiation
- R&D expenses
- $0.8 million vs. $1.3 million
- Quarter ended September 30, 2026 vs. quarter ended September 30, 2025
- G&A expenses
- $1.0 million vs. $1.8 million
- Quarter ended September 30, 2026 vs. quarter ended September 30, 2025
- Net loss
- $1.8 million vs. $3.1 million
- Quarter ended September 30, 2026 vs. quarter ended September 30, 2025
- Cash
- $4.4 million
- As of September 30, 2026
Previous Earnings Reports
-
Reported Q3 financial results and CAReS interim gains in weight and lean body mass.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
glp-1 receptor agonists medical
intraocular pressure medical
multiple ascending dose medical
pharmacokinetics medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Continued Progress Across Pipeline Supports Expanded Therapeutic Opportunities
SOLANA BEACH, Calif., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, obesity, dermatologic, ophthalmic, and neurological conditions, today provided a business update and announced its financial and operational results for the third quarter ended September 30, 2026.
Business Highlights
ART27.13:
- Expanding Development Opportunities in Obesity: New nonclinical findings demonstrated approximately
20% weight loss with ART27.13 monotherapy, comparable to semaglutide, and approximately40% weight loss when combined with semaglutide in a diet-induced obesity animal model. The combination also further improved oral glucose tolerance and increased bone mineral density, effects not observed in any other treatment group. The results support ART27.13’s potential as a treatment for obesity, both independently and in combination with GLP-1 therapies, expanding beyond cancer supportive care towards a total weight management solution. - Strengthening Intellectual Property and Clinical Potential: Artelo filed a provisional patent application covering ART27.13 for obesity and combination use with GLP-1 receptor agonists. Artelo also received Notices of Allowance in the U.S. and Japan for patent claims covering the intended commercial formulation of ART27.13. The U.S. patent, once issued, is expected to extend protection through 2041. The Company continues to pursue multiple indications, supported by previously reported Phase 2 CAReS interim findings demonstrating improvements in body weight, lean body mass and physical activity in patients experiencing cancer-related anorexia and weight loss.
- Second Phase 2 Study Initiated in Glaucoma: Enrollment is already underway for the investigator-led DREAM trial, a Phase 2 study evaluating whether oral daily treatment with ART27.13 can lower intraocular pressure in people with glaucoma or ocular hypertension.
ART26.12:
- Advancing First-in-Human FABP5 Inhibitor for Non-Opioid Pain Treatment: Plans for ART26.12, the first selective fatty acid binding protein 5 (FABP5) inhibitor evaluated in humans, anticipate a Phase 1 multiple ascending dose (MAD) study to initiate in the fourth quarter of 2026. Previously reported single ascending dose results demonstrated favorable safety and tolerability, predictable pharmacokinetics and exposure levels supporting further clinical development.
- Strengthening Scientific Evidence and Industry Engagement: Artelo presented ART26.12 data at the International Association for the Study of Pain (IASP) 2026 World Congress on Pain and at BIO-Europe 2026, highlighting its differentiated mechanism of action and potential to address significant unmet needs in chronic pain. Reported nonclinical findings indicate ART26.12's potential across multiple pain indications, including chemotherapy-induced peripheral neuropathy, spinal cord injury and osteoarthritis, where it achieved pain relief levels comparable to naproxen with significantly less gastric tissue damage.
“We are gratified that our programs are moving closer to key clinical milestones and revealing new development opportunities,” said Gregory D. Gorgas, President and Chief Executive Officer. “Our immediate priority is advancing ART26.12 into its next stage of clinical testing, where we aim to amplify the encouraging results observed to date. At the same time, the expanding potential of ART27.13 is generating opportunities with potential strategic partners in significant new therapeutic markets.”
Q3 2026 Financial Results
- R&D Expenses: Research and development expenses were
$0.8 million for the quarter ended September 30, 2026, compared to$1.3 million for the quarter ended September 30, 2025. - G&A Expenses: General and administrative expenses were
$1.0 million for the quarter ended September 30, 2026, compared to$1.8 million in the quarter ended September 30, 2025. - Net Loss: For the quarter ended September 30, 2026, net loss was
$1.8 million , or$3.19 per basic and diluted common share, compared to a net loss of$3.1 million for the quarter ended September 30, 2025. - Cash and Investments: Cash totaled
$4.4 million as of September 30, 2026.
About Artelo Biosciences
Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that modulate lipid-signaling pathways, with a diversified pipeline addressing significant unmet needs in obesity, anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. Led by an experienced executive team collaborating with world-class researchers and technology partners, Artelo applies rigorous scientific, regulatory, and commercial expertise to maximize stakeholder value. More information is available at www.artelobio.com and X: @ArteloBio.
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, as amended, including those relating to the Company’s product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth or partnering opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission, including but not limited to: our ability to raise additional capital in the future; the inherent uncertainties of preclinical and clinical research, including the possibility that results observed in nonclinical animal models may not be predictive of, or replicated in, human clinical trials; the uncertainty of patent protection and the potential for intellectual property challenges; the highly competitive nature of the pharmaceutical industry, including the market for pain therapeutics; the risk that third-party market projections may not materialize or that the Company may not be able to participate in projected market opportunities; the timing, content and availability of the Company’s presentation at the IASP 2026 World Congress on Pain; and our ability to enter into partnering or licensing arrangements on acceptable terms, or at all. Readers are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by applicable securities laws.
Investor Relations Contact:
Crescendo Communications, LLC
Tel: 212-671-1020
Email: ARTL@crescendo-ir.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were Artelo Biosciences’ third-quarter 2026 financial results?
Artelo reported a $1.8 million net loss, or $3.19 per basic and diluted common share, for the quarter ended September 30, 2026, compared with a $3.1 million loss a year earlier. Research and development expenses were $0.8 million, administrative expenses were $1.0 million, and quarter-end cash was $4.4 million.
What did Artelo’s ART27.13 obesity study show?
In a diet-induced obesity animal model, ART27.13 produced approximately 20% weight loss alone, comparable to semaglutide, and approximately 40% with semaglutide. The combination also further improved oral glucose tolerance and increased bone mineral density, effects not observed in any other treatment group. These were nonclinical findings, not human obesity trial results.